Cellular Intelligence: Virtual-cell models get Parkinson’s clinical test

Acquiring Novo Nordisk’s Parkinson’s disease cell therapy moves Cellular Intelligence from model-building into the clinic, where the former Somite Therapeutics can test whether AI-guided insights into cell signaling and differentiation can improve regenerative medicines.

On Monday, the Boston-based company acquired global rights to STEM-PD, an off-the-shelf, hESC-derived dopaminergic progenitor therapy already in a Phase I/II trial in Europe. The program has fast track designation and IND clearance from FDA. Novo will take an equity stake in Cellular Intelligence and is eligible for milestones and royalties; financial terms were not disclosed...